Tetraphase Pharmaceu (TTPH) Stock News
NASDAQ:TTPH - Nasdaq -
TTPH Latest News, Press Relases and Analysis
The Daily Biotech Pulse: Merck's Wonder Cancer Drug Snags Another Approval, Decision Day For Zogenix, UniQure Out-Licenses Gene Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) ACADIA...
La Jolla to acquire Tetraphase Pharma (NASDAQ:LJPC)
La Jolla Pharmaceutical (NASDAQ:LJPC) and Tetraphase Pharmaceuticals (NASDAQ:TTPH) have entered into a definitive merger agreement, under which La Jolla would acquire Tetraphase, through a tender off
Mentions: LJPC
Price Over Earnings Overview: Tetraphase Pharmaceutical
Looking into the current session, Tetraphase Pharmaceutical Inc. (NASDAQ: TTPH) shares are trading at $2.73, after a 3.80% increase. Moreover, over the...
La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.
La Jolla Pharma makes unsolicited bid for Tetraphase Pharma (NASDAQ:TTPH)
The bidding competition for Tetraphase Pharmaceuticals (NASDAQ:TTPH) is not over yet. La Jolla Pharmaceuticals (NASDAQ:LJPC) has submitted an unsolicited bid of $43.0M in cash plus an additional $16.0
Tetraphase Announces Receipt of Proposal from La Jolla Pharmaceutical Company, Determination of Superior Offer and Notice to Melinta
FIVE, TTPH, APT and SALT among after-hours movers
Gainers: LAKE +32.9%. DUO +27.5%. TTPH +17.6%. FIVE +10.6%. APT +10.5%.Losers: VRNT -9.2%. CSII -8.1%. SALT -7.9%. LEAF -6.8%. ELVT -6.6%.
Melinta inks agreement for Tetraphase buy (NASDAQ:ACRX)
Emerging victorious in a bidding joust with AcelRx Pharmaceuticals (NASDAQ:ACRX), Melinta Therapeutics (NASDAQ:MLNT) enters into a definitive merger agreement with Tetraphase Pharmaceuticals (NASDAQ:T
Healthcare - Top 5 Gainers / Losers
Gainers: Sientra (NASDAQ:SIEN) +25%. Tetraphase Pharmaceuticals (NASDAQ:TTPH) +20%. Immunic (NASDAQ:IMUX) +17%. China Jo-Jo Drugstores (NASDAQ:CJJD) +15%. Tenet Healthcare (NYSE:THC) +15%.Losers: Tita
Tetraphase up 61% premarket after Melinta emerges as top bidder (NASDAQ:TTPH)
Nano cap Tetraphase Pharmaceuticals (NASDAQ:TTPH) is up 61% premarket on robust volume. Yesterday, initial suitor AcelRx Pharmaceuticals announced that it would not revise its latest offer for the com
Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals
AcelRx drops bid for Tetraphase Pharma (NASDAQ:ACRX)
AcelRx Pharmaceuticals (NASDAQ:ACRX) announces that it does not intend to revise its latest cash-and-stock bid for Tetraphase Pharmaceuticals (NASDAQ:TTPH) and expects the termination of their previou
AcelRx Pharmaceuticals Announces It Will Not Further Revise Its Offer to Acquire Tetraphase
Mentions: ACRX
WU, CSWC, TTPH and MGI among after-hours movers
Gainers: MGI +33.6%. TTPH +11.2%. UBX +7.7%. PRT +6.6%. WU +4.8%.Losers: HHR -12.2%. PRCP -10.3%. PUMP -7.6%. CSWC -6.9%. INVH -3.1%.
Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRx
AcelRx tops Melinta with new bid for Tetraphase Pharma (NASDAQ:TTPH)
Tetraphase Pharmaceuticals (TTPH -11.1%) has entered into a second amendment of its merger agreement with AcelRx Pharmaceuticals (ACRX) after the latter submitted a revised bid of $0.5872 in cash plus
Mentions: ACRX
Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased Consideration
AcelRx Pharmaceuticals Announces Revised Merger Agreement with Tetraphase
Mentions: ACRX
Melinta tops AcelRx bid for Tetraphase Pharma (NASDAQ:ACRX)
Undeterred by a revised bid from AcelRx Pharmaceuticals (NASDAQ:ACRX), Melinta Therapeutics (NASDAQ:MLNT) has sweetened its offer for Tetraphase Pharmaceuticals (NASDAQ:TTPH) to $34M in cash plus $16.